In conclusion, these results suggest that macrophage BTK is activated in IgA nephropathy and it is involved in inflammatory response through NF-κB signaling pathway, which implicates that it may be an appropriate therapeutic target, and BTK inhibitors may be a novel treatment strategy for IgA nephropathy. This evidence concerns the gene BTK and IgA glomerulonephritis.